Skip to main content
. 2020 Nov 6;35(7):1949–1963. doi: 10.1038/s41375-020-01075-3

Fig. 7. Decytabine exert inhibitory effects on the Bcor−/−Dnmt3a−/− leukemic population.

Fig. 7

A WBC count changes (i) in leukemic Bcor−/−Dnmt3a−/− mice pre and 3 days after the end of the treatment with decytabine (DEC), cytarabine (ARAC) and vehicle (VEI). (ii) WBC follow up (right) during and post the treatment with DEC, ARAC and VEI in leukemic mice. B (i) Total number of GR1 + MAC1 + , MAC1 + GR1-, cKIT+, CD41+, B220+ and CD3+ cells in PB 3 days after DEC, ARAC and vehicle treatment in leukemic Bcor−/−Dnmt3a−/−, mice (n = 11,11,12). (ii) Total number of TER119+ and TER119 + /cKIT+ cells in PB 3 days after DEC, ARAC and vehicle treatment in leukemic Bcor−/−Dnmt3a−/− mice (n = 11,11,12). (iii) Spleen weight to total body weight ratio in Bcor−/−Dnmt3a−/− leukemic mice after each indicated treatment (N = 4,4,3). C Kaplan–Mayer plot of leukemic Bcor−/−Dnmt3a−/− mice survival after DEC, ARAC and VEI treatment to the indicated genotypes (n = 10 to 9 per genotype) (p < 0.0001, Logrank Test). *p < 0.05, **p < 0.01; ***p < 0.001 Wilcoxon matched pairs test.